January 3, 2014Blood
How I treat target-specific oral anticoagulant–associated bleeding
Why the study?
How should severe or life-threatening target-specific oral anticoagulant-associated bleeding be managed in the absence of specific antidotes?
Population
Patients with severe or life-threatening target-specific oral anticoagulant (TSOAC)-associated bleeding
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support PCC or aPCC in severe TSOAC bleeding without antidotes; leaves open need for randomized trials.
Structured PICO
How should severe or life-threatening target-specific oral anticoagulant-associated bleeding be managed in the absence of specific antidotes?
P
Population
Patients with severe or life-threatening target-specific oral anticoagulant (TSOAC)-associated bleeding
I
Intervention
Nonspecific therapies that promote formation of fibrin (prothrombin complex concentrate [PCC], activated PCC [aPCC], and recombinant factor VIIa) added to maximum supportive therapy
In the absence of specific antidotes, the addition of PCC or aPCC to maximum supportive therapy may be reasonable for managing severe or life-threatening TSOAC-associated bleeding.
Cite This Study
Siegal et al. (2014) studied this question.